• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by KALA BIO Inc.

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALA alert in real time by email
    SC 13G 1 tm2428381d7_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    KALA BIO, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    483119202
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x   Rule 13d-1(b)

     

    ¨    Rule 13d-1(c)

     

    ¨    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 483119202

     

    1 Names of reporting persons
    ADAR1 Capital Management, LLC
    2 Check the appropriate box if a member of a group (see instructions)

    (a) ¨

    (b) x

    3 SEC use only
     
    4 Citizenship or place of organization
    Texas
    Number of shares beneficially owned by each reporting person with: 5 Sole voting power
    0
    6 Shared voting power
    477,698(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    477,698(1)
    9 Aggregate amount beneficially owned by each reporting person
    477,698
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    9.99%(2) 
    12 Type of reporting person (see instructions)
    OO
           

     

    (1) Includes (i) 281,446 shares of common stock, par value $0.001 per share (“Common Stock”) held by ADAR1 Partners, LP, (ii) 24,621 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 171,631 shares of Common Stock underlying Series H Preferred Stock held by ADAR1 Partners, LP as of November 5, 2024. Excludes 126,769 shares of Common Stock underlying Series H Preferred Stock held by ADAR Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC., ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
    (2) Based on 4,610,139 shares of Common Stock of KALA BIO, Inc. (the "Issuer") outstanding as of November 11, 2024 reported in Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 12, 2024.

     

    2

     

     

    CUSIP No. 483119202

     

    1 Names of reporting persons
    ADAR1 Capital Management GP, LLC
    2 Check the appropriate box if a member of a group (see instructions)

    (a)  ¨

    (b)  x

    3 SEC use only
     
    4 Citizenship or place of organization
    Texas
    Number of shares beneficially owned by each reporting person with: 5 Sole voting power
    0
    6 Shared voting power
    480,431(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    480,431(1)
    9 Aggregate amount beneficially owned by each reporting person
    480,431
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    9.99%(2) 
    12 Type of reporting person (see instructions)
    OO
           

     

    (1) Includes (i) 281,446 shares of Common Stock by ADAR1 Partners, LP and (ii) 198,985 shares of Common Stock underlying Series H Preferred Stock held by ADAR1 Partners, LP as of November 5, 2024. Excludes 60,715 shares of Common Stock underlying Series H Preferred Stock held by ADAR Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
    (2) Based on 4,610,139 shares of Common Stock of the Issuer outstanding as of November 11, 2024 reported in Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 12, 2024.

     

    3

     

     

    CUSIP No. 483119202

     

    1 Names of reporting persons
    Daniel Schneeberger
    2 Check the appropriate box if a member of a group (see instructions)
    (a)  ¨
    (b)  x
    3 SEC use only
     
    4 Citizenship or place of organization
    Switzerland

    Number of shares beneficially owned by each reporting person with: 

    5 Sole voting power
    0
    6 Shared voting power
    477,698(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    477,698(1)
    9 Aggregate amount beneficially owned by each reporting person
    477,698
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    9.99%(2) 
    12 Type of reporting person (see instructions)
    IN
           

     

    (1) Includes (i) 281,446 shares of Common Stock held by ADAR1 Partners, LP, (ii) 24,621 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 171,631 shares of Common Stock underlying Series H Preferred Stock held by ADAR1 Partners, LP as of November 5, 2024. Excludes 126,769 shares of Common Stock underlying Series H Preferred Stock held by ADAR Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
    (2) Based on 4,610,139 shares of Common Stock of the Issuer outstanding as of November 11, 2024 reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 12, 2024.

     

    4

     

     

    Item 1(a) Name of issuer:

     

    KALA BIO, Inc.

     

    Item 1(b) Address of issuer’s principal executive offices:

     

    1167 Massachusetts Avenue, Arlington, MA 02476

     

    Item 2(a) Name of person filing:

     

    This Schedule is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”):

     

      (i) ADAR1 Capital Management, LLC (“ADAR1 Capital Management”);
      (ii) ADAR1 Capital Management GP, LLC (“ADAR1 General Partner”); and
      (iii) Daniel Schneeberger (“Mr. Schneeberger”).

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

     

    Item 2(c) Citizenship:

     

      (i) ADAR1 Capital Management is a Texas limited liability company;
      (ii) ADAR1 General Partner is a Texas limited liability company; and
      (iii) Mr. Schneeberger is a citizen of Switzerland.

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    Item 2(e) CUSIP No.:

     

    483119202

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ¨ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); 

     

      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); 

     

    5

     

     

      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); 

     

      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

     

      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); 

     

      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); 

     

      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). 

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    Item 4. Ownership

     

    ADAR1 Capital Management, LLC

     

    Amount beneficially owned:   477,698 
    Percent of class:   9.99%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   477,698 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   477,698 

     

    ADAR1 Capital Management GP, LLC

     

    Amount beneficially owned:   480,431 
    Percent of class:   9.99%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   480,431 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   480,431 

     

    6

     

     

    Daniel Schneeberger

     

    Amount beneficially owned:   477,698 
    Percent of class:   9.99%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   477,698 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   477,698 

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

      ADAR1 CAPITAL MANAGEMENT, LLC
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger 
      Manager
       
      ADAR1 CAPITAL MANAGEMENT GP, LLC
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger 
      Manager
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger, in his individual capacity

     

    8

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of common stock, par value $0.001 per share of KALA BIO, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

     

    In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of November 14, 2024.

     

      ADAR1 CAPITAL MANAGEMENT, LLC
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger 
      Manager
       
      ADAR1 CAPITAL MANAGEMENT GP, LLC
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger 
      Manager
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger, in his individual capacity

     

    9

     

    Get the next $KALA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KALA

    DatePrice TargetRatingAnalyst
    3/30/2022Neutral → Underweight
    JP Morgan
    8/6/2021$14.00 → $11.00Buy
    HC Wainwright & Co.
    8/6/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      -- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 -- -- Raised $10.75 million in private placement financing with participation from SR One, Cormorant Asset Management, Woodline Partners and another life sciences-focused investor -- -- Cash resources of $51.2 million as of December 31, 2024, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies

      3/31/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

      ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 5, 2025. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com. About KALA BIO, Inc. K

      2/26/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO Announces Chief Executive Officer Transition

      ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

      2/12/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kala Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Kala Pharmaceuticals from Neutral to Underweight

      3/30/22 7:39:31 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Kala Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously

      8/6/21 6:36:47 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Kala Pharmaceuticals from Overweight to Neutral

      8/6/21 5:55:07 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by KALA BIO Inc.

      SC 13G - KALA BIO, Inc. (0001479419) (Subject)

      11/14/24 4:49:42 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by KALA BIO Inc.

      SC 13D - KALA BIO, Inc. (0001479419) (Subject)

      7/8/24 8:54:55 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by KALA BIO Inc.

      SC 13D - KALA BIO, Inc. (0001479419) (Subject)

      6/28/24 4:11:51 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Bazemore Todd

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      3/10/25 8:00:08 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Officer Brazzell Romulus K

      4/A - KALA BIO, Inc. (0001479419) (Issuer)

      1/10/25 8:00:36 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Bazemore Todd was granted 10,100 shares and sold $15,207 worth of shares (1,993 units at $7.63), increasing direct ownership by 10% to 91,147 units (SEC Form 4)

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      1/7/25 8:14:03 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Leadership Updates

    Live Leadership Updates

    See more
    • KALA BIO Announces Chief Executive Officer Transition

      ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

      2/12/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

      -- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 ---- Received FDA Fast Track designation for KPI-012 for the treatment of PCED ---- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and sever

      5/9/23 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor

      ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala's clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in this role on a part time basis while continuing his ongoing position as Director of Cornea and External Disease and the Co-Director, Refractive Su

      3/29/23 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    SEC Filings

    See more
    • KALA BIO Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - KALA BIO, Inc. (0001479419) (Filer)

      4/11/25 4:09:11 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by KALA BIO Inc.

      424B5 - KALA BIO, Inc. (0001479419) (Filer)

      3/31/25 8:45:34 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by KALA BIO Inc.

      10-K - KALA BIO, Inc. (0001479419) (Filer)

      3/31/25 8:03:08 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Financials

    Live finance-specific insights

    See more
    • Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

      ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on August 30, 2022. The

      8/18/22 4:01:00 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      -- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and prov

      8/11/22 7:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

      ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651. To access a live webcast and subsequent archived recording of the call, please visit the "Presentations" se

      8/8/22 9:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Baker Bros. Advisors Lp bought $2,000,000 worth of shares (310,559 units at $6.44) (SEC Form 4)

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      12/31/24 4:00:18 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care